AMSTERDAM – Debate about whether patients taking direct-acting antiviral (DAA) therapies for hepatitis C viral (HCV) infections are at risk of developing liver cancer after achieving sustained virologic response (SVR) continued unabashed Thursday at the European Association for the Study of the Liver's (EASL) annual International Liver Congress.